Lloyd Dunlap
Articles by Lloyd Dunlap
| 3 min read
New biotech startup focuses on next generation therapeutic peptides in oncology, immuno-oncology and immune diseases
| 3 min read
New research indicates the act of creating iPSCs for clinical use is unlikely to pass on cancer-causing mutations to patients
| 2 min read
Spark adds new program for leading cause of inherited retinal disease
| 3 min read
Alzheon announces efficacy analyses of prior tramiprosate Phase 3 studies on key clinical endpoints in
Alzheimer’s disease
| 3 min read
To include study of onapristone in combination with abiraterone
| 3 min read
In reviewing the proposal, the Affymetrix board of directors notes that Origin appears to be a newly-
formed shell entity with no assets of which Affymetrix is aware, and whose sole source of funding for the proposed transaction is $1.5 billion in potential
debt commitments. Based on the analysis performed by Affymetrix' advisers, $1.5 billion falls materially short of the funds that would be required to
complete the transaction,
| 3 min read
Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for
biotherapeutics discovery, development and manufacturing
| 2 min read
Treatment with selective
orexin-2 receptor antagonist MIN-202 improves symptoms of depression, independent from its effect on sleep
| 3 min read
Rapastinel may sidestep cognitive deficits seen with ketamine
| 2 min read
Envigo shares findings on the effectiveness of its rat models in examining susceptibility and
attenuation to HSV-2 infection
| 3 min read
With an initial $5-million donation, goal for Biogen and Target ALS is $20 million more in corporate funding
